Brian A. Crowe

Vaccine R&D
Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

The soluble cytoplasmic tail of CD45 regulates T-cell activation via TLR4 signaling.

The soluble cytoplasmic tail of CD45 regulates T-cell activation via TLR4 signaling.

Journal: European journal of immunology
Published: February 22, 2021

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector.

Modulation of the liver immune microenvironment by the adeno-associated virus serotype 8 gene therapy vector.

Journal: Molecular therapy. Methods & clinical development
Published: July 06, 2020

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Journal: Clinical and vaccine immunology : CVI
Published: September 05, 2014

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.

Journal: PloS one
Published: May 16, 2014

Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.

Journal: Clinical and vaccine immunology : CVI
Published: April 18, 2014

Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: comparison of two ELISAs, immunoblot and CXCL13 testing.

Laboratory diagnosis of Lyme neuroborreliosis is influenced by the test used: comparison of two ELISAs, immunoblot and CXCL13 testing.

Journal: Journal of the neurological sciences
Published: March 25, 2014

Lyme disease vaccination: safety first - authors' reply.

Lyme disease vaccination: safety first - authors' reply.

Journal: The Lancet. Infectious diseases
Published: December 21, 2013

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses.

Journal: PloS one
Published: September 06, 2013

Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.

Journal: PloS one
Published: August 26, 2013

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Journal: Human vaccines & immunotherapeutics
Published: July 17, 2013

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

Journal: The Lancet. Infectious diseases
Published: May 14, 2013

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.

A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.

Journal: Vaccine
Published: January 24, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026